Stock MRNS MARINUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Marinus Pharmaceuticals, Inc.

Equities

MRNS

US56854Q2003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		Pre-market 08:49:44 am
1.44 USD +20.00% Intraday chart for Marinus Pharmaceuticals, Inc. 1.46 +1.39%
Apr. 17 Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating MT
Apr. 16 Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Truist Adjusts Marinus Pharmaceuticals' PT to $10 From $25, Keeps Buy Rating
MT
Baird Downgrades Marinus Pharmaceuticals to Neutral, Price Target at $2
MT
RBC Downgrades Marinus Pharmaceuticals to Sector Perform From Outperform, Slashes Price Target to $3 From $24, Keeps Speculative Risk
MT
North American Morning Briefing : Powell Comments, -2-
DJ
Sector Update: Health Care Stocks Softer Late Afternoon
MT
Marinus Pharmaceuticals Shares Fall After Phase 3 Trial Interim Analysis of Ganaxolone
MT
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
BU
Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial
CI
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review
AQ
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
BU
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) added to S&P Pharmaceuticals Select Industry Index
CI
Marinus Pharmaceuticals Ztalmy Gains Approval From UK Medicines and Healthcare Products Regulatory Agency
MT
UK Approves Marinus Pharmaceuticals' Ztalmy for Rare Genetic Disorder
MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT
Marinus Pharmaceuticals Q4 Net Loss Wider Than Expected While Revenue Misses Forecast; Shares Drop Premarket
MT
Marinus Pharmaceuticals Q4 Net Loss Narrows, Revenue Higher; Shares Plunge After-Hours
MT
Transcript : Marinus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Marinus Pharmaceuticals: Q4 Earnings Snapshot
AQ
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRNS Stock
  4. News Marinus Pharmaceuticals, Inc.